Viekira Pak™ (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)

What is Viekira Pak™?

On December 19, 2014 the U.S. Food and Drug Administration approved an interferon-free prescription medication, Viekira Pak™ (ombitasvir, paritaprevir, ritonavir and dasabuvir tablets), co-packaged tablets to be taken with or without ribavirin. Viekira Pak™ is indicated for the treatment of patients with genotype 1 chronic hepatitis C infection including those with compensated cirrhosis. It is also approved for HCV/HIV co-infection and for people who have had a liver transplant. It is not for those with advanced cirrhosis (decompensated).

Viekira Pak™ includes:

• 12.5 mg ombitasvir, a hepatitis C virus NS5A inhibitor,
• 75 mg paritaprevir, a hepatitis C virus NS3/4A protease inhibitor,
• 50 mg ritonavir, a CYP3A inhibitor, and
• 250 mg dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.

Patients take two of the ombitasvir/paritaprevir/ritonavir combination tablets daily in the morning with a meal. The additional dasabuvir tablet is taken twice daily – once in the morning and once in the evening with a meal.

Last Updated: May 2015